Evidence map›Paper›PMID 37216009›Full record

ArticleHGG advances2023

The mitochondrial genome as a modifier of autism versus cancer phenotypes in

Ruipeng Wei, Lamis Yehia, Ying Ni, Charis Eng

Open access · goldAbstract read
In one paragraph

Article in HGG advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ruipeng WeiGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Lamis YehiaGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Ying NiCenter for Immunotherapy & Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Charis EngGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Cleveland Clinic Lerner College of Medicine · USCleveland Clinic · US

Funding

Modeling Autism and Comorbid Cancer Risk in Individuals with Germline PTEN MutationsR01HD105049 · NICHD · CLEVELAND CLINIC LERNER COM-CWRU · PI Ying Ni, Sujata Patil · 2022 to 2026
$1.8M
NICHD NIH HHS R01 HD105049
6 · The paper itself

Abstract

Cancer and autism spectrum disorder/developmental delay (ASD/DD) are two common clinical phenotypes in individuals with germline

Indexed as

Autism Spectrum DisorderAutistic DisorderGenome, MitochondrialHamartoma Syndrome, MultipleThyroid NeoplasmsDNA Copy Number VariationsDNA, MitochondrialHumansPhenotypePTEN PhosphohydrolaseDNA, MitochondrialPTEN PhosphohydrolasePTEN protein, humanautism spectrum disordercancergenomic modifiersmitochondrial DNA (mtDNA)PTEN

Identifiers

PMID37216009
PMCPMC10193119
OpenAlexW4366815177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.